Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

Published:2009-07-14 Issue:3 Volume:101 Page:465-472
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Souglakos J,Philips J,Wang R,Marwah S,Silver M,Tzardi M,Silver J,Ogino S,Hooshmand S,Kwak E,Freed E,Meyerhardt J A,Saridaki Z,Georgoulias V,Finkelstein D,Fuchs C S,Kulke M H,Shivdasani R A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605164.pdf

Reference26 articles.

1. Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634

2. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de BF, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–671

3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954

5. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408–3415

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes;Scientific Reports;2024-02-04

2. Omics-based molecular classifications empowering in precision oncology;Cellular Oncology;2024-01-31

3. Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting;Journal of Cancer Research and Clinical Oncology;2023-07-19

4. Impact of encorafenib on survival of patients with BRAF V600E -mutant metastatic colorectal cancer in a real-world setting;2023-07-11

5. Structure optimization of an F-indole-chalcone (FC116) on 4-methoxyphenyl group and therapeutic potential against colorectal cancers with low cytotoxicity;Bioorganic Chemistry;2023-06